BLOG

Trial Drug Shows Promise in Treating Cognitive Impairment Associated with Schizophrenia

Last week, privately-owned Cerevance released data from a Phase Ib biomarker study of its oral compound, CVN058, evaluating the potential of the medication as a treatment for cognitive impairment associated with schizophrenia (CIAS).